Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine

NCT05249829 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05249829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
February 16, 2022
Completion date
June 23, 2023
Enrollment
3,548 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2